Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Topic

You searched for:

Demystifying the Delivery and Adverse Event Management of Bispecific Antibodies in the Community Setting Authors: R. Kajdic Hodzic1, J. Koff2, A. Mehta3, E. Budde4, S. Devarakonda5, D. Moore6, J. Brody7, B. Wuthrich8, R. Mancini9; C. Martin10; C. Mangir11; A. Harvey11; N. Colwell1; E. Plotkin1; M. Kisiel1; A. Lile1 1The Association of Cancer Care Centers; 2Winship Cancer Institute of Emory …
Opportunities exist to expand the adoption of BsAbs. Community oncology practices, which serve the majority of patients with cancer, are uniquely positioned to administer these innovative treatments and enhance patient outcomes. ASSOCIATION OF CANCER CARE CENTERS Readiness for Bispecific Antibody Therapy: Initiation and Maintenance Phases LANDSCAPE ANALYSIS HIGHLIGHTS Financial …
HSCO 2025 ASH Symposium Wednesday January 21, 2025 3660 On the Rise Honolulu, HI Attendee Roster First Name Last Name Title Account Name Dan Goodwin Hemolytic Anemia Specialist Agios Pharmaceuticals Amber Rose Executive Oncology Account Specialist Astra Zeneca Craig Boddy Hematologist Hawaii Pacific Health Amanda Christian Oncology Account Manager Jazz Pharmaceuticals …
DATE SOCIETY MEETING CITY/STATE VENUE Event Type Tuesday, January 21, 2025 HSCO HSCO ASH Symposium Honolulu, HI 3660 On the Rise Non-Display Event Corporate Members ONLY Display EventSaturday, February 1, 2025 WAHO WAHO 2025 Best of SABCS Milwaukee, WI The Pfister Port Jefferson, NY Danfords Hotel, Marina & Spa Networking Event Platinum & Premier Members ONLY …
This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. TACOS ONCOLOGY DRUG NEWSLETTER D E C E M B E R 2 0 2 4 FDA APPROVAL Nilotinib (Danziten) The first indication of nilotinib (Danziten) tablets that necessitates no mealtime restrictions has been approved by the FDA. The agent …
Request for Proposals (RFP) Improving the Precision Oncology Care Pathway I. Introduction Association of Cancer Care Centers (ACCC) and Lilly are collaborating to offer community cancer centers a grant opportunity seeking proposals for Quality Improvement (QI)/ Implementation Science (IS) initiatives that reduce clinical care gaps for patients with solid tumors. We are looking …
ASSOCIATION OF CANCER CARE CENTERS 1 Preparing for Your Poster Session at the ACCC 51st Annual Meeting & Cancer Center Business Summit Creating Your Poster As you develop your poster, determine which aspects of your research project are most interesting and important and consider how you can communicate that information visually. Posters are most effective when they mix visuals …
ACCC 51st Annual Meeting & Cancer Center Business Summit March 5 – March 7, 2025 Capital Hilton, Washington DC Wednesday, March 5, 2025 Time Session 7:00 AM – 7:00 PM Registration Open  7:00 AM – 8:00 AM Breakfast for Capitol Hill Attendees 8:00 AM – 4:00 PM ACCC Capitol Hill Day ACCC Capitol Hill Day gives ACCC members the opportunity to meet with members of Congress …
E03223009 BHC US Bayer M3P Patient Tear Pad Spanish Oct24_ES_v02.indd Opte por el plan de pago de recetas de Medicare a partir del 15 de octubre de 2024 Aproveche los cambios de Medicare 2025 para ayudar a manejar los costos de su receta médica Bajo la Parte D de Medicare, sus gastos cotidianos de 2025 tienen un límite máximo de $2000. También puede optar por participar en el Plan …
Opt in to the Medicare Prescription Payment Plan starting October 15, 2024 TAKE ADVANTAGE OF 2025 Medicare changes to help manage your prescription costs Under Medicare Part D, your 2025 out-of-pocket costs are capped at $2,000. You can also elect to participate in the Medicare Prescription Payment Plan—an optional program to help manage your out-of-pocket drug costs by spreading them …
Enhancing Early-Stage NSCLC Care: Streamlining Biomarker Testing and Multidisciplinary Coordination Through Quality Improvement Initiatives Authors: Jennifer Aversano, MSN, RN, OCN, ONN-CG1; Jennifer Tseng, MD2; Stephanie Brinton, MD3; Jose Galeas, MD4; Bianca Alvarez, MPH5; Ashley Lile, MPH5; Molly Kisiel, NP5; Joseph Kim, MD, MPH, MBA, FACHE6; Matthew P. Smeltzer, PhD7; Elana Plotkin5 1. …
1 Copyright© 2024 ADVI Health. All Rights Reserved. Copyright© 2024 ADVI Health. All Rights Reserved. TxSCO Update November 14, 2024 ADVI & HillCo 2 Copyright© 2024 ADVI Health. All Rights Reserved. Federal Updates 3 Copyright© 2024 ADVI Health. All Rights Reserved. Democrat- controlled House Republican- controlled House Republican- controlled …
This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. TxSCO ONCOLOGY DRUG NEWSLETTER N O V E M B E R 2 0 2 4 FDA APPROVAL Optune Lua The FDA has granted approval to Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic non– small …
This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. SCOS ONCOLOGY DRUG NEWSLETTER N O V E M B E R 2 0 2 4 FDA APPROVAL Optune Lua The FDA has granted approval to Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic non– small …
This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. TACOS ONCOLOGY DRUG NEWSLETTER N O V E M B E R 2 0 2 4 FDA APPROVAL Optune Lua The FDA has granted approval to Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic non– small …
This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. NCOA ONCOLOGY DRUG NEWSLETTER N O V E M B E R 2 0 2 4 FDA APPROVAL Optune Lua The FDA has granted approval to Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic non– small …
IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS • Diarrhea: Diarrhea, sometimes severe, can occur in patients treated with OGSIVEO. Diarrhea occurred in 84% of patients treated with OGSIVEO, and included Grade 3 events in 16% of patients. Median time to first diarrhea event was 9 days (range: 2 to 434 days). Monitor patients and manage using antidiarrheal medications. Modify dose as …
PowerPoint Presentation Bispecific Therapies for Mature Lymphoid Malignancies Steven Bair, MD Assistant Professor of Medicine University of Colorado SOM Disclosures ✹ I have no relevant disclosures or conflicts of interest. ✹My spouse has an ongoing consultancy with Kyra Oncology. Introduction Introduction CU Lymphoma Team Manali …
PowerPoint Presentation Bispecific Antibodies in Plasma Cell Dyscrasias Aman Godara, MD Assistant Professor Division of Hematology & Hematologic Malignancies Huntsman Cancer Institute, University of Utah Email: amandeep.godara@hci.utah.edu Disclosure Consultancy: Janssen, Sanofi Objectives • Bispecific antibodies in Multiple Myeloma (MM) ➢ Efficacy …
ORM - Cincinnati 11.20 Salutation First Name Last Name Designation Title Account Name Mrs. Liz A Linville Director Margaret Mary Health Mrs. Jackie Austin B.S. Director Revenue Cycle Outpatient Services Southern Illinois Healthcare Ms. Terri Barbeau Senior Clinical Account Specialist Abbvie Mrs. Jeannine Barker Senior Area …